Servier Licenses IPA


Mountain View, CA and Croissy sur Seine, France – June 09, 2005 – Ingenuity announced today the upcoming release of its flagship product, IPA.

Servier and Ingenuity announced today that the Institut de Recherches Servier has licensed IPA, an innovative technology that enables scientists to simultaneously analyze multiple genomic and proteomic datasets to rapidly gain biological insight and understanding.

“IPA will become a key component of our genomics technology platform and we plan to fully integrate the application into our current drug discovery strategy,” stated Dr. Brian P. Lockhart, Director of the Molecular, Pharmacology, and Pathophysiology Department at Institut de Recherches Servier.

“We are pleased to have Servier join the growing list of pharmaceutical organizations who are working with us to bring the IPA application and knowledge framework to their scientific staff,” stated Dr. Rudy Potenzone, Senior Vice President of Product Management at Ingenuity. “We will work closely with the scientists at Servier to ensure that Ingenuity continues to provide cutting edge solutions that help researchers to understand biological mechanisms, identify and capture key pathways, and easily share results and insights with colleagues and collaborators. These capabilities will ultimately assist our customers in making faster and better scientific and business decisions.”

Scientists are using IPA across many application areas, from target identification and validation to biomarkers, predictive toxicology, and patient stratification. IPA makes use of the Ingenuity Pathways Knowledge Base, the world’s largest curated database consisting of millions of individually modeled relationships between proteins, genes, complexes, cells, tissues, drugs, and diseases. Fully functional complimentary trials are available to qualified scientists at


SERVIER is the largest privately-owned pharmaceutical company in France, and is the second-ranked French drug group worldwide. SERVIER products are available in 140 countries across the five continents. The SERVIER Group employs 16,000 people worldwide, with 2500 in Research & Development and allocates approximately 25% of its turnover to R& D. Servier’s main therapeutic products are used to treat diabetes, cardiovascular diseases, neuropsychiatric disorders, cancer, and bone and joint diseases. SERVIER has obtained regulatory approval for over 30 drugs originating from its own research over the past 30 years, and currently has 33 molecules in Research and Development, 5 of which are in phase III and 2 of which are undergoing registration. In the next 18 months Servier is going to make available to the medical profession three innovative pharmaceutical specialties in the field of osteoporosis, cardiovascular diseases and treatment of depression. The core Discovery Research facility in chemistry and pharmacology is located in the Ile-de-France at the Suresnes Research Centre, and also in the Croissy-sur-Seine Research Centre which specializes in brain disease, neurobiology, neuropsychopharma-cology and oncology.

About Ingenuity Systems

Ingenuity Systems is helping life science researchers explore and understand biological systems that are foundational to human health and disease. Ingenuity delivers capabilities and expertise to researchers through analysis software, genome-scale computable network databases, and knowledge management services and infrastructure, resulting in increased productivity and faster drugs to market. The company was founded in 1998 and is headquartered in Mountain View,